Dg Capital Management Inc Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Dg Capital Management Inc reduced its stake in Amgen by 41.58% during the most recent quarter end. The investment management company now holds a total of 15,330 shares of Amgen which is valued at $2.3 Million after selling 10,910 shares in Amgen , the firm said in a disclosure report filed with the SEC on May 11, 2016.Amgen makes up approximately 2.31% of Dg Capital Management Inc’s portfolio.

Other Hedge Funds, Including , Jupiter Asset Management Ltd reduced its stake in AMGN by selling 5,050 shares or 6.28% in the most recent quarter. The Hedge Fund company now holds 75,310 shares of AMGN which is valued at $11.5 Million. Amgen makes up approx 0.49% of Jupiter Asset Management Ltd’s portfolio.Pioneer Investment Management Inc reduced its stake in AMGN by selling 35,978 shares or 18.56% in the most recent quarter. The Hedge Fund company now holds 157,866 shares of AMGN which is valued at $24.1 Million. Amgen makes up approx 0.09% of Pioneer Investment Management Inc’s portfolio.Teachers Advisors Inc boosted its stake in AMGN in the latest quarter, The investment management firm added 29,378 additional shares and now holds a total of 1,405,401 shares of Amgen which is valued at $215.3 Million. Amgen makes up approx 0.39% of Teachers Advisors Inc’s portfolio.Beck Mack Oliver reduced its stake in AMGN by selling 2,500 shares or 17.12% in the most recent quarter. The Hedge Fund company now holds 12,100 shares of AMGN which is valued at $1.9 Million. Amgen makes up approx 0.07% of Beck Mack Oliver’s portfolio. Investment Centers Of America Inc sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 3,501 shares of AMGN which is valued $554,208.

Amgen opened for trading at $152.35 and hit $153.86 on the upside on Monday, eventually ending the session at $153.27, with a gain of 0.60% or 0.92 points. The heightened volatility saw the trading volume jump to 24,15,093 shares. Company has a market cap of $115,139 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Citigroup Initiated Amgen on Feb 25, 2016 to “Neutral”, Price Target of the shares are set at $165.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.